期刊
AUTOIMMUNITY REVIEWS
卷 8, 期 7, 页码 591-594出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2009.02.008
关键词
Rheumatoid arthritis; B-lymphocyte; Rituximab
类别
B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据